Postpartum Depression Treatment Denied? How to Fight Back

Postpartum depression (PPD) affects an estimated one in eight new mothers in the United States, with rates even higher for postpartum anxiety and postpartum PTSD. Yet despite being a serious, recognized medical condition, treatment for PPD is routinely denied by insurance companies — often in ways that directly violate federal mental health parity law.

If your PPD treatment has been denied, this guide explains your rights and your options.

The Scope of Postpartum Mental Health Conditions

"Postpartum depression" is often used as an umbrella term, but the clinical picture is broader:

• Postpartum Depression (PPD): Major depressive episode occurring within the first year after delivery
• Postpartum Anxiety: Excessive worry, panic attacks, intrusive thoughts
• Postpartum PTSD: Triggered by traumatic birth experiences
• Postpartum OCD: Intrusive thoughts with compulsive behaviors
• Postpartum Psychosis: A rare but severe condition requiring immediate psychiatric care

All of these are diagnosable, treatable mental health conditions — and all are subject to the same insurance protections as any other condition.

Mental Health Parity: The Core Legal Protection

The Mental Health Parity and Addiction Equity Act (MHPAEA) requires that mental health and substance use disorder benefits be offered at parity with medical/surgical benefits. Specifically:

• Financial requirements (copays, deductibles) for mental health care cannot be more restrictive than for comparable medical care
• Treatment limitations (visit limits, Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization requirements, day limits) cannot be more restrictive for mental health care
• Non-quantitative treatment limitations (NQTLs) — like medical necessity criteria and step therapy requirements — must be applied equally

For PPD treatment, this means: if your plan covers inpatient hospitalization for physical conditions, it must cover inpatient psychiatric care on comparable terms. If outpatient physical therapy has minimal prior authorization requirements, intensive outpatient mental health programs should not face dramatically more burdensome requirements.

ACA and Essential Health Benefits

The ACA includes mental health and substance use disorder services as essential health benefits for individual and small group plans. This means PPD treatment — including therapy, medication, and inpatient care when necessary — cannot be excluded from these plans.

Zulresso and Zuranolone: PPD-Specific Medications

Two medications have received FDA approval specifically for postpartum depression:

• Brexanolone (Zulresso): The first FDA-approved PPD medication, administered as a 60-hour IV infusion in a certified healthcare setting. Denials are common due to the inpatient-like administration and cost. If your physician prescribed Zulresso, challenge the denial as a MHPAEA violation — comparable IV infusions for physical conditions are generally covered without similar barriers.
• Zuranolone (Zurzuvae): An oral PPD medication approved in 2023 for PPD and MDD. Expect formulary and step therapy denials for this newer medication. Request a formulary exception with your prescribing physician's documentation.

Common PPD Treatment Denials

Therapy Session Limits

Plans that impose arbitrary visit limits on psychotherapy for PPD (for example, limiting to 10 sessions per year) may violate MHPAEA if comparable physical therapy visits face no similar limits. Challenge session limits by requesting the insurer's methodology for setting them and comparing to physical health benefits.

Inpatient or Residential Denial

Severe PPD, especially postpartum psychosis, may require inpatient psychiatric care. Insurers frequently deny inpatient mental health stays by applying more restrictive medical necessity criteria than they use for medical inpatient stays. This is a classic MHPAEA violation. Request the specific criteria used and compare them to criteria for inpatient medical-surgical admissions.

Step Therapy for Medication

Insurers may require you to try cheaper antidepressants before approving FDA-indicated PPD medications. If your physician determines a specific medication is clinically appropriate, they can write a step therapy exception letter citing clinical reasons the standard alternatives are inappropriate.

Intensive Outpatient Program (IOP) or Partial Hospitalization Denial

IOPs and PHPs are often the right level of care for moderate-to-severe PPD that doesn't require 24-hour hospitalization. Denials for these programs are very common and often violate MHPAEA. Document your treating clinician's recommendation for the specific level of care.

How to Appeal

1. Request the specific criteria used for the denial and compare to medical/surgical analogues — this is the MHPAEA analysis
2. Get a letter from your treating clinician documenting diagnosis, severity, and clinical necessity of the specific treatment
3. File a MHPAEA complaint with your state insurance department if internal appeals fail — regulators take parity violations seriously
4. Request External Independent Review: Complete Guide" class="auto-link">external review — independent reviewers overturn PPD denials at a meaningful rate when clinical documentation is strong

Fight Back With ClaimBack

Postpartum depression is a medical emergency for many new mothers, and insurance barriers to treatment have real consequences. ClaimBack helps you identify parity violations, draft formal appeals, and get the treatment you and your baby need.

Start your appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: What's the Difference?